




RealRate

PHARMACEUTICAL 2024

Oncotelic Therapeutics Inc
Rank 161 of 309



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Oncotelic Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Oncotelic Therapeutics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is 206%, being 7.0% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	272
Cost of Goods Sold	0
Intangible Assets	5,988
Liabilities, Current	16,505
Liabilities, Non-Current	0
Other Assets	23,755
Other Compr. Net Income	0
Other Expenses	6,083
Other Liabilities	1,898
Other Net Income	-1,558
Other Revenues	70
Property and Equipment	0
Research and Development	61
Selling, General and Administrative Expense	574

Output Variable	Value in 1000 USD
Assets	30,015
Liabilities	18,403
Expenses	6,718
Revenues	70
Stockholders Equity	11,612
Net Income	-8,206
Comprehensive Net Income	-8,206
BaseVar	28,382
ECR before Limited Liability	71%
Economic Capital Ratio	206%